Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of Ambrisentan in PAH (ARIES-E)
NCT00578786Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2004
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by Gilead Sciences. Started Feb 2004; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00578786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00578786.